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Research article Pretreatment with statins improves early outcome 
in patients with first-ever ischaemic stroke: a 
pleiotropic effect of statins or a beneficial effect of 
hypercholesterolemia?
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Abstract
Background: Data from different studies suggest a favourable association between pretreatment with statins or 
hypercholesterolemia and outcome after ischaemic stroke. We examined whether there were differences in in-hospital 
mortality according to the presence or absence of statin therapy in a large population of first-ever ischaemic stroke 
patients and assessed the influence of statins upon early death and spontaneous neurological recovery.
Methods: In 2,082 consecutive patients with first-ever ischaemic stroke collected from a prospective hospital-based 
stroke registry during a period of 19 years (1986-2004), statin use or hypercholesterolemia before stroke was 
documented in 381 patients. On the other hand, favourable outcome defined as grades 0-2 in the modified Rankin 
scale was recorded in 382 patients.
Results: Early outcome was better in the presence of statin therapy or hypercholesterolemia (cholesterol levels were 
not measured) with significant differences between the groups with and without pretreatment with statins in in-
hospital mortality (6% vs 13.3%, P = 0.001) and symptom-free (22% vs 17.5%, P = 0.025) and severe functional limitation 
(6.6% vs 11.5%, P = 0.002) at hospital discharge, as well as lower rates of infectious respiratory complications during 
hospitalization. In the logistic regression model, statin therapy was the only variable inversely associated with in-
hospital death (odds ratio 0.57) and directly associated with favourable outcome (odds ratio 1.32).
Conclusions: Use of statins or hypercholesterolemia before first-ever ischaemic stroke was associated with better early 
outcome with a reduced mortality during hospitalization and neurological disability at hospital discharge. However, 
statin therapy may increase the risk of intracerebral haemorrhage, particularly in the setting of thrombolysis.
Background
Recent data have shown that lipid-lowering treatment
using HMG-CoA reductase inhibitors (statins) is effec-
tive in primary and secondary stroke prevention in high
risk patients for vascular disease [1,2]. Furthermore, sta-
tin therapy discontinuation has been associated to unfa-
vourable stroke outcome [3,4]. Statins induce several
potential neuroprotective effects including an increase in
cerebral perfusion, activation of survival signals, synthe-
sis of heat shock protein 27, and increases in angiogenesis
and neurogenesis [5]. Statins may protect the brain when
administered shortly after injury but also afford protec-
tive effects in patients taking statins for hypercholester-
olemia before the injury [4]. For patients with acute
ischaemic stroke premorbid statin use was associated
with smaller lesion volume and better functional out-
come [1,6,7] and high levels of total cholesterol were
associated with a increased rate of recovery from disabil-
ity in basic activities of daily living among hospitalized
older adults [8] and decreased risk of physical disability
after stroke [9].
To further contribute to determine the effects of statins
on early outcome in patients with first-ever ischaemic
stroke, data of 2,082 consecutive ischaemic stroke
patients included in a prospective stroke registry during a
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19-year period were analysed. The objectives of the study
were as follows: a) to compare early outcome in the sub-
sets of acute ischaemic stroke patients with and without
statin use before stroke and b) to assess the effect of statin
therapy on in-hospital mortality and spontaneous early
neurological recovery.
Methods
Since January 1986, the Hospital of Sagrat Cor (an acute
care 350-bed teaching hospital in the city of Barcelona
serving a population of ~250,000 people) has had an
ongoing hospital-based stroke registry. Data from first-
ever stroke patients are entered following a standardized
protocol with 186 items regarding demographics, anam-
nestic data (vascular risk factors, underlying illnesses,
concomitant treatments), clinical features, laboratory and
neuroimaging data, complications and outcome. Data
included in the registry up to December 2004, the partic-
ular time at which 3,808 patients had been entered in the
d a t a b a s e  w e r e  r e v i e w e d .  C l a s s i f i c a t i o n  o f  s u b t y p e s  o f
stroke and definition of cardiovascular risk factors were
those used by our group in previous studies [10]. For the
purpose of this study, the group of 2,082 consecutive
patients with first-ever ischemic stroke was selected.
Prior to conducting the study, approval was obtained
from Ethical Committee on Clinical Research of the hos-
pital.
All patients were admitted to the hospital within 48
hours of onset of symptoms. On admission, demographic
characteristics; salient features of clinical and neurologi-
cal examination and results of laboratory tests (blood cell
count, biochemical profile, serum electrolytes, urinaly-
sis); chest radiography; and twelve-lead electrocardiogra-
phy; and brain CT and/or MRI were recorded. Other
investigations, such as angio-MRI, echo-Doppler of the
supra-aortic trunks, arterial digital subtraction angiogra-
phy, B-mode echocardiography and lumbar puncture
were performed at the discretion of the neurologist in
charge.
Degree of clinical disability at discharge from the hospi-
tal was evaluated according to the modified Rankin scale
(mRS), a 6-item functional disability scale (grade 0 = no
symptoms at all; grade 1 = symptoms but able to carry out
all usual activities; grade 2 = slight disability but able to
carry out activities without assistance; grade 3 = moder-
ate disability, requiring some help but able to walk with-
out assistance; grade 4 = moderately severe disability; and
grade 5 = severe disability: bedridden, incontinent, and
requiring constant nursing care and attention). The mRS
was obtained prospectively. The outcome of patients was
classified as favourable outcome (spontaneous neurologi-
cal recovery or minimal stroke associated disability at dis-
charge (mRS grades 0-2), and unfavourable outcome (not
improved, mRS grades 3-5 or in-hospital death). The cut-
off point of the Rankin scale was defined before the study.
Causes of death were analysed according to criteria of Sil-
ver et al. [11]. Moreover, outcome variables included car-
diac events (acute myocardial infarction, heart failure, or
tachyarrhythmia); respiratory events (pulmonary embo-
lism, atelectasis, or lower respiratory tract infection);
infectious complications, neurological complications
(progressive stroke, early seizures or early stroke recur-
rence) and urinary complications.
Statistical analysis
Data from patients with and without statin use before
stroke were analysed using the Student's t  test or the
Mann-Whitney U test for the comparison of continuous
variables and the chi-square (χ2) test (with Yates correc-
tion when necessary) for the comparison of categorical
variables. In addition, data from patients with and with-
out favourable outcome (mRS grades 0-2) were compared
with the Student's t test, χ2 test and the analysis of vari-
ance (ANOVA) when appropriate. Statistical significance
for inclusion in the multivariate analysis was set at P <
0.02. Variables related to either in-hospital death or
favourable outcome in the univariate analyses plus sex
and age were subjected to multivariate analysis with a
logistic regression procedure. All variables selected were
included in the initial model. Criteria for variables to
remain in the model were based on the statistical signifi-
cance of the Wald's test (P < 0.05) and on the comparison
of the estimated coefficient of each variable with the coef-
ficient of the model containing only this variable. Vari-
ables that did not contribute to the model according to
these criteria were removed and the model readjusted.
The new model after removing a variable was compared
with the former model with the likelihood ratio test. Age
was used in multivariate analysis as a continuous variable
with a constant odds ratio for each year. In the two mod-
els, in-hospital mortality (coded as alive = 0 and death =
1) and favourable outcome (coded as absence = 0, pres-
ence = 1) were the dependent variables. Odds ratio (OR)
and 95% confidence intervals (CI) were calculated from
the beta coefficients and standard errors. The hypothesis
that the logistic regression model adequately fitted the
date was tested by means of the goodness of fit χ2 test
[12]. The SPSS-PC+ and BMDP computer programmes
were use for statistical analyses.
Results
A total of 381 patients were receiving statin treatment at
the time of brain infarction. These patients accounted for
18.3% of all cases of first-ever ischaemic stroke included
in the stroke registry. Statin-treated patients as compared
with the untreated group were significantly younger and
the proportion of patients aged ≥ 85 years of age was also
significantly lower. When differences in outcome vari-Arboix et al. BMC Neurology 2010, 10:47
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ables between statin-treated and untreated patients were
analysed, early outcome was better in the statin group
(Table 1), with a significantly higher percentage of favour-
able outcome (mRS grade 0) at the time of hospital dis-
charge, a significantly lower percentage of patients with
severe functional limitation at hospital discharge as well
as lower rates of infectious complications and respiratory
events during hospitalisation. The proportion of patients
with neurological complications was also lower in the sta-
tin-treated group and almost reached statistical signifi-
cance. In-hospital mortality was 13.3% (n = 226) among
untreated patients and 6.0% (n = 26) among statin-treated
patients. Causes of death were cerebral herniation in 7
patients, sepsis in 6, myocardial infarction in 4, sudden
death in 2, lower respiratory tract infection in 2 and
unknown cause in 2. The median (25th-75th percentile)
length of hospital stay was 10 (8-18) days in patients
treated with statins as compared with 12 (8-20) days in
untreated patients (P = 0.001).
Of the total series of 2,028 patients with first-ever
ischaemic stroke, favourable outcome was recorded in
382 patients (18.8%). On the other hand, the overall in-
hospital mortality rate was 11.9% (n = 249). Results of
univariate analysis in ischemic stroke patients according
to vital status (alive, death) and presence or absence of
favourable outcome (mRS grade 0-2) at hospital dis-
charge are shown in Table 2. Patients with unfavourable
outcome (death or mRS grades 3-5) compared with those
with favourable outcome (early neurological recovery or
minimal stroke associated disability at discharge) were
significantly older and had more frequently ischaemic
heart disease, atrial fibrillation, congestive heart failure
and chronic obstructive pulmonary disease (COPD) as
v a s c u l a r  r i s k  f a c t o r s .  W i t h  r e g a r d  t o  c l i n i c a l  v a r i a b l e s,
sudden onset, early seizures, nausea/vomiting, altered
consciousness, limb weakness, sensory symptoms and
hemianopia were also significantly more frequent among
patients with unfavourable outcome. In the statins pre-
treatment group, not only a significantly higher percent-
age of patients were discharged alive from the hospital
(19.5% vs 9.2%) but also there was a higher percentage of
patients with favourable outcome (22% vs 17.5%) than in
the untreated group (Table 2). As shown in Table 3, the
frequency of favourable outcome and in-hospital mortal-
Table 1: Results of univariate analysis: differences in outcome variables between first-ever ischaemic stroke patients with 
and without pretreatment with statins
Data Statin use P value
Yes (n = 381) No (n = 1,701)
Male sex 194 (50.9) 793 (46.6) 0.072
Age, years, mean (SD) 71.8 (11.1) 75.7 (12.3) 0.000
Age, years ≥ 85 years 44 (11.5) 380 (22.3) 0.000
Cardiac events 17 (4.5) 78 (4.6) 0.523
Respiratory events 21 (5.5) 162 (9.5) 0.006
Infectious complications 37 (9.7) 223 (13.1) 0.039
Neurological complications 28 (7.3) 173 (10.2) 0.053
Favourable outcome, mRS 
grades 0-2
84 (22) 298 (17.5) 0.025
Unfavourable outcome, mRS 
grades 3-5
25 (6.6) 196 (11.5) 0.002
In-hospital mortality 23 (6.0) 226 (13.3) 0.000
mRS: modified Rankin scale.
Percentages in parenthesis unless otherwise stated.Arboix et al. BMC Neurology 2010, 10:47
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Table 2: Results of univariate analysis: differences in demographics, vascular risk factors and clinical features in acute 
ischaemic stroke patients according to outcome
Data Vital status at discharge Favourable outcome (mRS grades 0-2)
Alive Death P value Yes No P value
No. patients 1833 249 382 1700
Male sex 882 (48.1) 105 (42.2) 0.045 195 (51.0) 792 (46.6) 0.064
Age, years, mean (SD) 80.7 (8.9) 74.2(12.4) 0.000 74.6 (10.9) 75 (12.5) 0.014
Age, years ≥ 85 years 330 (18) 94 (37.8) 0.000 56 (14.7) 368 (21.6) 0.001
Vascular risk factors
Hypertension 997 (54.4) 123 (49.4) 0.077 200 (52.4) 928 (54.6) 0.244
Diabetes mellitus 421 (23) 50 (20.1) 0.174 93 (24.3) 78 (4.6) 0.142
Valvular heart disease 111 (6.1) 19 (7.6) 0.202 28 (7.3) 102 (6) 0.195
Ischaemic heart disease 168 (9.2) 57 (22.9) 0.001 50 (13.1) 269 (15.8) 0.102
Atrial fibrillation 481 (26.2) 128 (51.4) 0.000 94 (24.6) 515 (30.3) 0.015
Congestive heart failure 76 (4.1) 32 (12.9) 0.000 9 (2.4) 99 (5.8) 0.002
Transient ischaemic attack 204 (11.1) 33 (13.2) 0.187 48 (12.6) 189 (11.1) 0.235
Peripheral arterial disease 127 (6.9) 19 (7.6) 0.382 26 (6.8) 120 (7.1) 0.483
Chronic pulmonary disease 132 (7.2) 34 (13.7) 0.001 21 (5.5) 145 (8.5) 0.027
Obesity (BMI > 32.5 kg/m2) 97 (5.3) 6 (2.4) 0.060 24 (6.3) 79 (4.6) 0.116
Alcohol abuse (> 80 g/day) 47 (2.6) 9 (3.6) 0.219 7 (1.8) 49 (2.9) 0.166
Smoking (> 20 cigarettes/day) 193 (10.5) 14 (5.6) 0.013 32 (8.4) 175 (10.3) 0.149
Clinical features
Sudden onset 910 (49.6) 144 (57.8) 0.009 187 (49) 867 (51) 0.253
Headache 242 (13.2) 17 (6.8) 0.002 47 (12.3) 212 (12.5) 0.504
Dizziness 71 (3.9) 8 (3.2) 0.383 18 (4.7) 66 (3.9) 0.395
Early seizures 23 (1.2) 14 (5.6) 0.000 4 (1.0) 33 (1.9) 0.163Arboix et al. BMC Neurology 2010, 10:47
http://www.biomedcentral.com/1471-2377/10/47
Page 5 of 8
Nausea, vomiting 132 (7.2) 33 (13.2) 0.001 31 (8.1) 134 (7.9) 0.474
Speech disturbances 925 (50.5) 147 (59.0) 0.007 200 (52.4) 872 (51.3) 0.375
Altered consciousness 189 (10.3) 149 (59.8) 0.000 24 (6.3) 314 (18.5) 0.000
Limb weakness 1334 (72.8) 232 (93.2) 0.000 259 (67.8) 1307 (76.9) 0.000
Sensory symptoms 672 (36.7) 137 (55.0) 0.000 109 (28.5) 700 (41.2) 0.000
Hemianopia 293 (16) 76 (30.5) 0.000 30 (7.9) 339 (19.9) 0.000
Ataxia 122 (6.7) 7 (2.8) 0.008 25 (6.5) 104 (6.1) 0.414
Cranial nerve palsy 85 (4.6) 16 (6.4) 0.122 14 (3.7) 87 (5.1) 0.143
Statin use before stroke 356 (19.5) 23 (9.2) 0.000 84 (22) 297 (17.5) 0.025
Hospital stay, days, median (25th-75th 
interquartile range)
12 (9-20) 10 (4.7-23) 0.000 10 (8-14) 13 (8-22) 0.000
Percentages in parenthesis unless otherwise stated. Percentages are calculated for the total number in each column.
Table 2: Results of univariate analysis: differences in demographics, vascular risk factors and clinical features in acute 
ischaemic stroke patients according to outcome (Continued)
ity in relation to the use of statins when the study period
was divided into three periods (1986-1992; 1993-1998;
1999-2004) did not show significant differences, although
a decreasing trend in the mortality rate was observed.
In the logistic regression model statin use before
ischaemic stroke was the only variable inversely associ-
ated with in-hospital death (OR = 0.57) and directly asso-
ciated with favourable outcome (OR = 1.32) (Table 4).
Discussion
The present study adds evidence of the good functional
outcome at discharge from the hospital in patients who
were taking statins at the time of the ischaemic stroke
onset. The hypothesis that a statin therapy favours a bet-
ter early outcome is supported by a significantly lower in-
hospital mortality rate and a higher percentage of
patients with symptom-free at hospital discharge or min-
imal stroke associated disability at discharge in patients
with statins use than in those without statins pretreat-
ment.
These findings obtained in a large population of over
2,082 patients with first-ever acute ischaemic stroke are
consistent with several studies that reported an associa-
tion between premorbid statin use and better clinical
stroke outcome [13-16]. In a recent study of our group in
addition to the high frequency of cognitive impairment in
patients with multiple recurrent lacunes, an interesting
finding was the protective role of hyperlipidemia and sta-
tin therapy [17]. These data agree with those of a recent
clinical study that provide evidence that previous treat-
m e n t  w i t h  s t a t i n s  i s  a n  i n d e p e n d e n t  f a c t o r  a s s o c i a t e d
with good outcome in patients with ischaemic stroke
[18]. Atherothrombotic and small vessel strokes showed
the greatest benefit [17]. In the study of Yoon et al. [19],
Table 3: Frequency of favourable outcome and in-hospital mortality in statin users during the study period
Outcome 1986-1992*
(n = 146)
1993-1998
(n = 107)
1999-2004
(n = 128)
P value*
Favourable outcome (n = 84) 33 (22.6) 24 (22.4) 27 (21.1) 0,950
In-hospital mortality (n = 23) 18 (8.2) 6 (5.6) 5 (3.9) 0.319
*Statin use or hypercholesterolemia.Arboix et al. BMC Neurology 2010, 10:47
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statin pretreatment was significantly associated with an
improved functional outcome, and in the series of Reeves
et al., in-hospital mortality was 2.3% among statin users
compared to 6.6% in the subjects not treated with statins
[20]. In addition, in a meta-analysis totalled 70,388 par-
ticipants without established cardiovascular disease but
with cardiovascular risk factors, statin use was associated
with significantly improved survival and large reductions
in the risk of major cardiovascular events [3].
Statin drugs improve the outcome of ischaemic stroke
patients through different mechanisms, including better
cerebral collateral supply, a direct neuroprotective effect,
plaque stabilizing effects, and induction of angiogenesis,
neurogenesis and synaptogenesis [21-29]. The Stroke
Prevention with Aggressive Reduction in Cholesterol
(SPARCL) study found that the use of high-dose atorvas-
t a t i n  a s  c o m p a r e d  t o  p l a c e b o  i n  a c c u r a t e l y  s e l e c t e d
patients who had a stroke or TIA was associated with a
non-significant 13% risk reduction of non-fatal stroke
during a 5-year follow-up without improving survival
[30].
Alternative explanations focusing on potentially neuro-
protective properties of cholesterol should be considered.
Presumably, baseline cholesterol levels of the statin-
treated patients in this study were higher than those of
non-statin treated patients. Unfortunately, cholesterol
levels were not considered in the study. Cholesterol is
essential for normal cell membrane fluidity and it has
been speculated that high cholesterol concentrations may
have neuroprotective effect through increasing gamma-
glutamyltransferase. This enzyme plays a role in amino
acid uptake and transport and could reduce the neuro-
toxic effects of excitotoxic amino acids [31]. The proven
action of cholesterol as a buffer neutralizing free radicals
an also provide antioxidant protection [32,33]. This
action might limit the extent of cerebral infarction and
increasing the cellular recuperation capacity. In the
experimental model of myocardial ischemia, mice fed the
high-cholesterol diet for 12 weeks showed a significantly
lower area of myocardial infarction compared with mice
fed a normal diet [33]. Similarly, enrichment of cardio-
myocites cultures with free cholesterol resulted in an
increased tolerance to anoxia [34]. It has been shown that
elevated cholesterol concentrations were associated with
improved short-term health outcome after acute stroke of
any type [35], short-term mortality following ischaemic
stroke is higher in older patients with low total choles-
terol levels independent of a large number of factors [36]
and elevated levels of cholesterol were associated with
increased rate of recovery from disability in basic activi-
ties of daily living among acutely ill hospitalised older
patients [8]. Alternatively, we cannot exclude that ele-
vated cholesterol may simply represent an indicator of
good nutritional status. In line with this hypothesis, pre-
Table 4: Results of multivariate analyses
Variable β SE (β) Odds ratio (95% CI) P value
In-hospital mortality*
Atrial fibrillation 0.804 0.143 2.23 (1.69-2.96) 0.000
Congestive heart failure 0.728 0.235 2.07 (1.31-2.28) 0.002
Chronic obstructive pulmonary disease 0.539 0.216 1.71 (1.12-2.62) 0.013
Age 0.047 0.008 1.05 (1.03-1.06) 0.000
Statin use before stroke -0.568 0.234 0.57 (0.36-0.89) 0.002
Favourable outcome (mRS grades 0-2)†
Statin use before stroke 0.274 0.139 1.32 (1.01-1.73) 0.049
Congestive heart failure -0.926 0.353 0.40 (0.20-0.79) 0.009
* β = -6.029, SE (β) = 0.649, goodness of fit χ2 = 8.929, d.f. = 8, P = 0.348.
† β = -1.511, SE (β) = 0.065, goodness of fit χ2 = 0.041, d.f. = 1, P = 0.839.Arboix et al. BMC Neurology 2010, 10:47
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vious observations have identified strong correlations
between specific clinical markers of nutritional status (in
particular serum proteins) and the risk of subsequent in-
hospital adverse events [37].
Accordingly, hyperlipidemia may be considered, on the
one hand, a cardiovascular risk factor, but on the other
hand, and paradoxically, through a mechanism of neuro-
protection of the brain would be related to a lower neuro-
logical deficit and decreased mortality in patients with
acute cerebral ischaemia. In this respect, when prescrib-
ing pharmacological treatment, an excessive reduction of
total cholesterol levels may be avoided in order to control
the stroke risk factor without affecting the neuroprotec-
tion mechanism of hypercholesterolemia. On the basis of
this hypothesis, a prospective randomised trial with sta-
tins assessing the relationship between functional out-
come and mortality with different blood lipid levels in the
acute phase of cerebral ischaemia would be necessary.
The present findings should be interpreted taking into
account some limitations of the study. Cholesterol levels
were not measured in the study and it should be men-
tioned that thrombolytic therapy was introduced in our
hospital after the collection of the studied patients.
Therefore, is not possible to generalize the results in a
population of patients with stroke who undergo throm-
bolytic therapy. Although statin therapy may increase the
risk of intracerebral haemorrhage, it has been shown that
patients treated with statins before stroke had a better
response to thrombolytic therapy [38]. On the other
hand, in a study of gene expression of cerebral endothelial
cells in rat brain tissue, atorvastatin reduced exogenous
tPA-aggravated cerebral endothelial genes that mediate
thrombosis and blood-brain barrier permeability. This
could contribute to the beneficial effects of statins on
thrombolytic treatment of acute stroke [39].
Conclusions
The present findings indicate that pretreatment with sta-
tins, hypercholesterolemia or both in ischaemic stroke
patients could have neuroprotective effects with reduced
neurological deficits at presentation, lower early death
and dependency rate, thus increasing the chances for
good outcome. However, statin therapy may increase the
risk of intracerebral haemorrhage, particularly in the set-
ting of thrombolysis.
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